Anaplastic large cell lymphoma historical perspective

Anaplastic large cell lymphoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Anaplastic large cell lymphoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Anaplastic large cell lymphoma historical perspective On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Anaplastic large cell lymphoma historical perspective All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Anaplastic large cell lymphoma historical perspective
CDC on Anaplastic large cell lymphoma historical perspective
Anaplastic large cell lymphoma historical perspective in the news
Blogs on Anaplastic large cell lymphoma historical perspective
Directions to Hospitals Treating Anaplastic large cell lymphoma
Risk calculators and risk factors for Anaplastic large cell lymphoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sowminya Arikapudi, M.B,B.S. [2]

Overview

Anaplastic lymphoma kinase positive large B-cell lymphoma (ALK+ LBCL) was first described by Delsol and colleagues in 1997. In 2008, the World Health Organization (WHO) added anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma and anaplastic lymphoma kinase positive large B-cell lymphoma as provisional entities in the peripheral T-cell lymphoma classification.

Historical Perspective

Anaplastic lymphoma kinase positive large B-cell lymphoma (ALK+ LBCL) was first described by Delsol and colleagues in 1997. In 2008, the World Health Organization (WHO) added anaplastic lymphoma kinase (ALK) negative anaplastic large cell lymphoma and anaplastic lymphoma kinase positive large B-cell lymphoma as provisional entities in the peripheral T-cell lymphoma classification.